Biomarkers predicting response to corticosteroid therapy in asthma
- PMID: 16137188
- DOI: 10.2165/00151829-200504050-00002
Biomarkers predicting response to corticosteroid therapy in asthma
Abstract
International guidelines on the management of asthma support the early introduction of corticosteroids to control symptoms and to improve lung function by reducing airway inflammation. However, not all individuals respond to corticosteroids to the same extent and it would be an advantage to be able to predict the response to corticosteroid treatment. Several biomarkers have been assessed following treatment with corticosteroids including measures of lung function, peripheral blood and sputum indices of inflammation, exhaled gases and breath condensates. The most widely examined measures in predicting a response to corticosteroids are airway hyperresponsiveness, exhaled nitric oxide (eNO) and induced sputum. Of these, sputum eosinophilia has been demonstrated to be the best predictor of a short-term response to corticosteroids. More importantly, directing treatment at normalizing the sputum eosinophil count can substantially reduce severe exacerbations. The widespread utilization of sputum induction is hampered because the procedure is relatively labor intensive. The measurement of eNO is simpler, but incorporating the assessment of NO in an asthma management strategy has not led to a reduction in exacerbation rates. The challenge now is to either simplify the measurement of a sputum eosinophilia or to identify another inflammatory marker with a similar efficacy as the sputum eosinophil count in predicting both the short- and long-term responses to corticosteroids.
Similar articles
-
Changes in sputum eosinophils predict loss of asthma control.Am J Respir Crit Care Med. 2000 Jan;161(1):64-72. doi: 10.1164/ajrccm.161.1.9809100. Am J Respir Crit Care Med. 2000. PMID: 10619799
-
NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma.Eur Respir J. 1999 Jun;13(6):1391-5. Eur Respir J. 1999. PMID: 10445617
-
Can we predict sputum eosinophilia from clinical assessment in patients referred to an adult asthma clinic?Intern Med J. 2013 Jan;43(1):46-52. doi: 10.1111/j.1445-5994.2011.02565.x. Intern Med J. 2013. PMID: 21790924 Clinical Trial.
-
Clinical usefulness of inflammatory markers in asthma.Am J Respir Med. 2003;2(1):11-9. doi: 10.1007/BF03256635. Am J Respir Med. 2003. PMID: 14720018 Review.
-
A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).Thorax. 2012 Mar;67(3):199-208. doi: 10.1136/thx.2010.135574. Epub 2010 Oct 11. Thorax. 2012. PMID: 20937641 Review.
Cited by
-
Asthma progression and mortality: the role of inhaled corticosteroids.Eur Respir J. 2019 Jul 18;54(1):1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Eur Respir J. 2019. PMID: 31048346 Free PMC article. Review.
-
Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.J Allergy Clin Immunol. 2009 Feb;123(2):411-6. doi: 10.1016/j.jaci.2008.11.016. Epub 2009 Jan 3. J Allergy Clin Immunol. 2009. PMID: 19121860 Free PMC article.
-
Incense smoke: clinical, structural and molecular effects on airway disease.Clin Mol Allergy. 2008 Apr 25;6:3. doi: 10.1186/1476-7961-6-3. Clin Mol Allergy. 2008. PMID: 18439280 Free PMC article.
-
Metabolomics approach in allergic and rheumatic diseases.Curr Allergy Asthma Rep. 2014 Jun;14(6):445. doi: 10.1007/s11882-014-0445-5. Curr Allergy Asthma Rep. 2014. PMID: 24744271 Review.
-
Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial.JAMA. 2012 Sep 12;308(10):987-97. doi: 10.1001/2012.jama.10893. JAMA. 2012. PMID: 22968888 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical